( MENAFN - PR Newswire) Clinical Trials at American Society of Nephrology (ASN) – Kidney Week 2024 SAN FRANCISCO, Oct. 28, 2024 /PRNewswire/ -- Kind Pharmaceutical ("Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC"), a clinical-stage biopharmaceutical company focused on developing innovative medicines to treat hematological diseases and cancers, today announced that positive results of four clinical trials from its leading program AND017 to treat anemia in non-dialysis dependent chronic kidney disease (NDD-CKD) and dialysis-dependent chronic kidney disease (DD-CKD) were presented at annual meeting of American Society of Nephrology (ASN) Kidney Week in San Diego.
The four clinical trials are first-in-human trial in healthy subjects in Austria (clinical trial "AU-001", NCT04751539 ), food effects on pharmacokinetics (PK) in China (clinical trial "CN-101", NCT04712500 ), phase 2 trial in anemia in NDD CKD in both US and China (clinical trial "MN-201", NCT05035641 ), and phase 2 trial in anemia in DD CKD in both US and China (clinical trial "MN-202", NCT05265325 ). In the AU-001 double-blinded, placebo-controlled, first-in-human clinical trial in healthy subjects in Australia, AND017 demonstrated favorable linear oral pharmacokinetics (PK) with T1/2 (elimination half-life) between 11.9 h and 19.
7 h for the SAD part of trial (dosed from 1 mg to 50 mg) and T1/2 between 10.1 h and 19.4 h for the MAD part of trial (dosed from 4 mg to 30 mg QD for 10 days).
In this t.
